At a glance
- Andrew E. Roth brought the case on behalf of the Nasdaq-listed biotech under Section 16(b) of the Securities Exchange Act of 1934.
- According to the complaint, Anson entities executed five equity financing transactions with SELLAS between March 15, 2024 and Oct. 24, 2025, acquiring common stock and warrants representing about 122.1 million shares.
- Selectors can ask a manager that finances small-cap issuers through repeated warrant deals for its own tally of underlying shares by issuer.
A shareholder complaint filed Nov. 16 in the Southern District of New York seeks as much as $165.9 million from Anson Funds, alleging the Dallas and Toronto hedge fund complex took short-swing profits on its stake in SELLAS Life Sciences Group.
Andrew E. Roth brought the case on behalf of the Nasdaq-listed biotech under Section 16(b) of the Securities Exchange Act of 1934. The provision requires insiders, including any holder of more than 10% of a company's stock, to return profits from paired buy-sell trades made within six months. InvestmentNews first reported the filing. The complaint seeks disgorgement of profits "presently estimated to be not less than $54,749,932.28 and up to $165,907,405.23."
According to the complaint, Anson entities executed five equity financing transactions with SELLAS between March 15, 2024 and Oct. 24, 2025, acquiring common stock and warrants representing about 122.1 million shares. That is roughly 60.5% of the company's outstanding common stock as of June 30, 2026, and the funds sold about 117.6 million of those shares into the open market.
Selectors can ask a manager that finances small-cap issuers through repeated warrant deals for its own tally of underlying shares by issuer. The legal question is whether warrant caps set at 4.99% or 9.99% limit beneficial ownership or only the right to exercise. The complaint argues Rule 13d-3(d)(1)(i) counts the underlying shares, which would place the funds well above Section 16(b)'s 10% insider line.
The filing alleges each deal locked SELLAS into covenants barring it from raising equity from other investors for specified periods, a structure it calls a "vice grip" on the company's ability to raise capital. SELLAS disclosed "substantial doubt" about its ability to continue as a going concern across five consecutive quarterly reporting periods, according to the complaint, and the funds were the sole or 50% source of every equity financing in that period.
The complaint puts the funds' beneficial ownership as high as roughly 49.3% of outstanding common stock. It argues the warrants were acquired with "the purpose or effect of changing or influencing the control of" SELLAS. The allegations are unproven.
Complaint puts the SELLAS stake far above the 10% insider line
Share of SELLAS common stock outstanding (%), versus Section 16(b)'s 10% threshold
- Shares acquired60.5%
- Beneficial ownership alleged49.3%
- Warrant blocker cap, upper9.99%
- Warrant blocker cap, lower4.99%
Show as table
| Item | Value (%) |
|---|---|
| Shares acquired | 60.5% |
| Beneficial ownership alleged | 49.3% |
| Warrant blocker cap, upper | 9.99% |
| Warrant blocker cap, lower | 4.99% |
Reported by the Hedge Funds & Liquid Alts desk from InvestmentNews. Published . Corrections